We are a biopharmaceutical company focused on the acquisition, development and
commercialization of novel targeted therapies covering a spectrum of
blood-related cancers that offer a unique benefit to patients and healthcare
providers. Our goal is to build a profitable company by generating income from
products we develop and commercialize, either alone or with partners. We are
currently concentrating our efforts on treatments that target blood-related
cancers where there is an unmet medical need. In particular, we are primarily
focused on commercializing PIXUVRI ® (pixantrone), or PIXUVRI, in the European
Union, or the E.U., for the treatment of adult patients with multiply relapsed
or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and conducting a
Phase 3 clinical trial program of pacritinib for the treatment of adult patients
with myelofibrosis to support regulatory submission for approval in the U.S. and
Europe.